At Sandoz, our goal is to increase patient access to high-quality, affordable medicines. As a Pharmacy Business Consultant, you will drive sales growth, market share, and customer engagement across the Gold Coast territory through the acquisition, retention, and development of pharmacy customers.
You will build strong customer partnerships, deliver exceptional service, and position Sandoz as the partner of choice within the pharmacy channel while achieving territory sales and business objectives.
Key Accountabilities
Generic and biosimilar medicines are the backbone of the healthcare industry, and Sandoz touches the lives of nearly 500 million patients globally each year. While we are proud of this impact, we are driven to do more. Through investments in development capabilities, state-of-the-art production sites, strategic acquisitions, and partnerships, we are shaping the future of affordable, high-quality medicines.
Our momentum is powered by an open, collaborative culture and a team of talented, ambitious associates. We foster an agile and inclusive environment where diversity is valued, innovation is encouraged, and personal growth is supported.
Locally, we are proud to have achieved four consecutive Great Place to Work® certifications and to be recognised as the #1 Best Workplace in Pharmaceuticals & Biotechnology in Australia for 2025.
The future is ours to shape.
#Sandoz
Skills Desired

Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients.
More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz annually, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer.
Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
Read our community engagement guidelines: http://bit.ly/4ofoggc